Briacell Therapeutics
BCTX
18 hedge funds and large institutions have $17M invested in Briacell Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
9,170% more call options, than puts
Call options by funds: $3.99M | Put options by funds: $43K
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.42% less ownership
Funds ownership: 17.4% → 16.98% (-0.42%)
5% less capital invested
Capital invested by funds: $17.9M → $17M (-$861K)
5% less funds holding
Funds holding: 19 → 18 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$216K |
| 2 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$206K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$162K |
| 4 |
Morgan Stanley
New York
|
+$128K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$642K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$409K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$257K |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
-$30.7K |
| 5 |
CWP
Concord Wealth Partners
Abingdon,
Virginia
|
-$29.4K |
BCTX Hedge Fund Activity: Q3 2023 in Review
18 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q3 2023, worth a combined $17M — down 4.8% from $17.9M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BCTX and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 7 added.
The largest buyer was Susquehanna International Group, adding an estimated $216K. The largest seller was Wasatch Advisors, cutting an estimated $642K.
- 18 institutional investors held Briacell Therapeutics (BCTX) as of Q3 2023, down from 19 in Q2 2023.
- Funds reported $17M of Briacell Therapeutics stock for Q3 2023, down 4.8% quarter-over-quarter.
- 2 funds opened new Briacell Therapeutics positions in Q3 2023 and 3 closed out, a net change of -1 holder.
- The largest Briacell Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $216K added.
- The largest Briacell Therapeutics seller in Q3 2023 was Wasatch Advisors, an estimated $642K sold.
Based on aggregated 13F filings for Q3 2023.